Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients : authors' response
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:27 |
|---|---|
| Enthalten in: |
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases - 27(2021), 1 vom: 15. Jan., Seite 138-140 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Fiolet, Thibault [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
4QWG6N8QKH |
|---|
| Anmerkungen: |
Date Completed 04.01.2021 Date Revised 12.11.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.cmi.2020.10.002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM316496456 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM316496456 | ||
| 003 | DE-627 | ||
| 005 | 20231225161217.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.cmi.2020.10.002 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1054.xml |
| 035 | |a (DE-627)NLM316496456 | ||
| 035 | |a (NLM)33080383 | ||
| 035 | |a (PII)S1198-743X(20)30613-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Fiolet, Thibault |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effect of hydroxychloroquine with or without azithromycin on the mortality of COVID-19 patients |b authors' response |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.01.2021 | ||
| 500 | |a Date Revised 12.11.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Hydroxychloroquine |2 NLM | |
| 650 | 7 | |a 4QWG6N8QKH |2 NLM | |
| 650 | 7 | |a Azithromycin |2 NLM | |
| 650 | 7 | |a 83905-01-5 |2 NLM | |
| 650 | 7 | |a Chloroquine |2 NLM | |
| 650 | 7 | |a 886U3H6UFF |2 NLM | |
| 700 | 1 | |a Guihur, Anthony |e verfasserin |4 aut | |
| 700 | 1 | |a Rebeaud, Mathieu Edouard |e verfasserin |4 aut | |
| 700 | 1 | |a Mulot, Matthieu |e verfasserin |4 aut | |
| 700 | 1 | |a Peiffer-Smadja, Nathan |e verfasserin |4 aut | |
| 700 | 1 | |a Mahamat-Saleh, Yahya |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases |d 1995 |g 27(2021), 1 vom: 15. Jan., Seite 138-140 |w (DE-627)NLM094580014 |x 1469-0691 |7 nnns |
| 773 | 1 | 8 | |g volume:27 |g year:2021 |g number:1 |g day:15 |g month:01 |g pages:138-140 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.cmi.2020.10.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 27 |j 2021 |e 1 |b 15 |c 01 |h 138-140 | ||